HealthEd podcast featuring Associate Professor Nigel Crawford
MVEC's Associate Professor Nigel Crawford was recently a guest speaker on the HealthEd podcast series Going Viral. In this podcast, Nigel discusses the COVID-19 vaccine, its access equity, safety and manufacture; as well as antibody responses following COVID-19 disease and how this may impact our vaccine strategy.
To listen to this podcast please follow the link
NDTV speak to Professor Kanta Subbarao, Director of WHO Collaborating Centre for Reference and Research on Influenza
有关 COVID-19 疫苗的问题与解答
这 疫苗教育中心 (VEC) 在 费城儿童医院 (CHoP) 最近推出了一个新的资源页面，回答与 COVID-19 疫苗的开发和安全性相关的常见问题。我们还鼓励读者将自己的问题直接提交给 VEC 团队以获得答复。
要访问此计划，请点击链接 这里
冠状病毒疫苗进展报告：竞标赢得 COVID-19 疫苗竞赛的项目
全球有超过 140 种候选疫苗处于不同的开发阶段，ABC 考察了澳大利亚研究人员在生产安全有效的 COVID-19 疫苗方面所发挥的作用。
ABC：冠状病毒疫苗进展：竞标赢得 COVID-19 疫苗竞赛的项目
要进一步探索 COVID-19 疫苗开发流程并听取国内外专家的意见，请订阅我们的播客系列：
COVID-19 疫苗之路
The International Coalition of Medicines Regulatory Authorities (ICMRA) statement about confidence in vaccine safety and effectiveness
In a global effort to promote confidence in the safety of vaccines, the International Coalition of Medicines Regulatory Authorities (ICMRA) have released new documentation explaining the scientific evaluation process undertaken by vaccine candidates prior to licensing, as well as discussing the ongoing safety surveillance that continues after they have been approved for use. These documents are targeted for both health care professionals as well as consumers.
在这里阅读更多内容：
ICMRA statement about confidence in vaccine safety and effectiveness (for healthcare professionals)
ICMRA statement about confidence in vaccines (for the general public)
Zostavax safety advisory
The Therapeutic Goods Administration (TGA) have reiterated their advice that Zostavax should not be administered to immunocompromised individuals as it is associated with a risk of mild-serious complications. This advice follows a report of a new case of a patient who was taking hydroxychloroquine and a low dose of prednisolone who died three weeks after receiving the Zostavax vaccine. Whilst it was found that the Zostavax was administered in line with existing recommendations it is important that health professionals are aware of the potential of this kind of very rare adverse event.
在这里阅读更多内容：
And for more information on Zoster and to access the Zostavax GP Decision Aid refer to the MVEC：带状疱疹 immunisation reference page.
全国免疫追赶计算器 v1.0 现已推出
澳大利亚政府卫生部发布了第一版国家免疫补种计算器（NICC）。它可以在澳大利亚免疫手册网站上找到，并取代南澳大利亚卫生部主办的免疫计算器。
您可以在此处访问 NICC：
2020 年 7 月 1 日 - NIP 的变更
从今天开始，国家免疫计划 (NIP) 发生了变化，旨在加强对脑膜炎球菌和肺炎球菌疾病的保护。
您可以在此处阅读有关这些更改的更多信息：
临床更新：自 2020 年 7 月 1 日起国家免疫计划 (NIP) 时间表发生变化 - 给疫苗接种提供者的建议
您可以在此处查看更新后的维多利亚州免疫计划：
我们更新了以下页面以反映这些变化：
- MVEC：阿斯普利亚
- MVEC：原住民和托雷斯海峡岛民免疫建议
- MVEC：脑膜炎球菌病和疫苗
- MVEC：特殊风险和免疫抑制患者的脑膜炎球菌疫苗
- MVEC：推荐购买 20 岁以下的额外疫苗（无资金）
- MVEC：患有心脏病的儿童
- MVEC：早产儿免疫接种
Researchers at RCH show no association in vaccine uptake as a result of mandatory vaccination policies
Researchers from the Royal Children's Hospital in Melbourne's Specialist Immunisation Clinic and Drop in Centre have demonstrated mandatory immunisation policies 'No Jab, No Pay' and 'No Jab, No Play' show no association in vaccine uptake. Whilst the policies motivated attendance to a tertiary service, they don't appear to be changing vaccination behaviour as was the intention, with further evaluation required.
在这里阅读更多内容：
NCIRS 网络研讨会 - NIP 变更，您需要了解的内容
2020 年 7 月 1 日，国家免疫计划 (NIP) 的重要变化以及肺炎球菌、脑膜炎球菌和甲型肝炎疫苗接种的建议将生效。
NCIRS 举办了一场关于这些变化的网络研讨会，现在可以在线观看：